No Data
DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq
Food Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsight
DBV Technologies on Track for Lowest Close Since December 2025 -- Data Talk
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales
LifeSci Capital Maintains DBV Technologies(DBVT.US) With Buy Rating, Cuts Target Price to $45
Analysts Offer Insights on Healthcare Companies: DBV Technologies SA – American (DBVT) and Kalaris Therapeutics (KLRS)